Print Friendly Page
Molecular Analysis for Therapy Choice (MATCH)
This trial aims to establish whether patients with tumor mutations, amplifications or translocations in one of the genetic pathways of interest are likely to derive clinical benefit if treated with agents targeting that specific pathway.
The first step is to determine if you can participate in this study (screening step). The purpose of this screening step is to perform tests on your tumor cells to find out if your cancer has a gene change or mutation targeted by one or more of the drugs used in this study. The tests done on your tumor are investigational, and are done for the purpose of assigning a treatment to a MATCH substudy.
From the time of the biopsy, it will take up to 2-6 weeks to get the result of the genetic tests and it may take a few more days (less than a week) to assign a treatment if your genetic test shows you have results that match a treatment in the study. If there are no study drug(s) at this time that match your test results, you will no longer be in the study. If there are study drug(s) that match your test results, you will be asked to participate in the treatment part of this study.
- Must have confirmed diagnosis of solid tumors or lymphoma or multiple myeloma requiring therapy
- Must have progressed following at least one line of standard systemic therapy and there must not be other approval/standard therapy available that has been shown to prolong overall survival OR cannot receive other standard therapy that has been shown to prolonged survival due to medical issues
- Must have measurable disease
- Must have tumor amenable to image guided or direct vision biopsy and be willing and able to undergo a tumor biopsy for molecular profiling; patients with multiple myeloma other than plasmacytomas are to have a bone marrow aspirate to obtain tumor cells; biopsy must not be considered to be more than minimal risk to the patient
Applicable Disease Sites
Anal; Bladder; Brain/Central Nervous System; Breast; Cervix; Colon and Rectum; Endocrine cancers; Esophagus; Gastrointestinal cancers, other; Genitourinary cancers, other; Head and Neck; Hematologic cancers, other; Kidney; Leukemia; Liver; Lung; Lymphoma; Melanoma/Skin cancer; Multiple Myeloma; Ovary; Pancreas; Prostate; Sarcoma; Stomach; Testicular; Thyroid; Uterus; Vagina; Vulva
AZD1775; AZD4547; AZD5363; Ado-trastuzumab Emtansine; Afatinib; Aliqopa (Copanlisib); BMS-936558 (Nivolumab); BMS354825 (dasatinib); BVD-523FB (Ulixertinib); Binimetinib; Copanlisib; Defactinib (VS-6063); GDC-0032; GDC-0068; R05532961 (Ipatasertib); GDC-0449; GSK2636771; HER2/NEU (trastuzumab); Ipatasertib; LOXO-101; Larotrectinib (LOXO-101); MK-1775 (AZD1775); MLN0128; Mekinist (Trametinib); Nivolumab; Opdivo (Nivolumab); PD-0332991 (palbociclib); Sprycel (dasatinib); Tafinlor (dabrafenib); Trametinib; Ulixertinib; anti-pi85 her2 monoclonal antibody (trastuzumab); crizotinib; dabrafenib; dasatinib; herceptin (trastuzumab); palbociclib; pertuzumab; rhuMAb HER2 (trastuzumab); rhuMab2C4 (pertuzumab); sunitinib; trastuzumab
Mercy Health Systems, Janesville ; UW Hospital and Clinics; UWCCC 1 South Park